Personalized dendritic cell vaccine for advanced cancer after surgery
Official title: Adjuvant Treatment in Cancer Patients with Neoantigen-primed DC Vaccine : a Single-arm, Open-label, Prospective Clinical Trial
Run by Sichuan University · NCT04147078 · Data updated 2026-11-12
This study is testing a personalized vaccine made from patients' own tumor cells to see if it can help people with advanced cancer feel better after surgery.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Sichuan University Academic / other |
| Locations | 1 site (Chengdu, Sichuan) |
| Status | Recruiting |
| Started | June 1, 2019 |
| Main results expected | December 31, 2025 |
| Study ends | June 1, 2026 |
| Registry record updated | February 28, 2025 |
| Trial ID | NCT04147078 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are postoperative patients with confirmed locally advanced gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, or colorectal cancer who have undergone curative resection or ablation.
✕Probably not a fit
Patients with metastatic disease, co-existing malignancies, or significant immunological co-morbidities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study tests the safety and efficacy of a personalized dendritic cell vaccine for patients who have undergone surgery for locally advanced gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, and colorectal cancer. Participants will have their tumor tissues analyzed to identify neoantigens, which are then used to prime dendritic cells in vitro. The vaccine will be administered subcutaneously, and both adverse events and treatment responses will be closely monitored throughout the trial.
Why it matters
Potential benefit: If successful, this approach could enhance the immune response against cancer cells, potentially improving outcomes for patients with advanced cancers.
How similar studies have gone: While the approach of using personalized dendritic cell vaccines is promising, it is still considered novel and has not been extensively tested in this specific context.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants with a first diagnosis of gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer who have undergone a curative resection or ablation * Anticipated life time \> 3month * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 * Adequate organ functions Exclusion Criteria: * Any evidence of tumor metastasis or co-existing malignant disease * Tumor emergency * Abnormal coagulation condition * Contagious diseases, such as hepatitis B virus, hepatitis C virus, human immunodefficiency virus, tuberculosis infection * Concomitant tumors * Immunological co-morbidities
Where it's running
-
Qiu Li
Chengdu, Sichuan, China Recruiting
Study contacts
- Study coordinator: Qiu Li
- Email: liqiu@scu.edu.cn
- Phone: +86 028-85422589
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Testing MGC026 in patients with advanced solid tumors
This study is testing a new treatment called MGC026 to see if it can help adults with advanced solid tumors that can't be removed or have spread to other parts of the body.
-
Infusing iNKT and PD-1+ CD8+ T cells for advanced solid tumors
This study will try giving people with advanced lung, pancreatic, liver, stomach, or colon cancers infusions of iNKT cells and PD-1+ CD8+ T cells to see if tumors shrink and survival improves.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
-
First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors
This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.
-
XYA02 in advanced solid tumors
This trial tests XYA02 in adults with MUC1-expressing advanced or relapsed solid tumors to see if it is safe, tolerable, and can shrink tumors.
-
First-in-human test of HH160 in people with advanced solid tumors
HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.